GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (TSX:CSCI) » Definitions » Research & Development

Cosciens Biopharma (TSX:CSCI) Research & Development : C$11.67 Mil (TTM As of Mar. 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Cosciens Biopharma's Research & Development for the three months ended in Mar. 2025 was C$1.63 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was C$11.67 Mil.


Cosciens Biopharma Research & Development Historical Data

The historical data trend for Cosciens Biopharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma Research & Development Chart

Cosciens Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.89 3.89 1.86 2.74 11.83

Cosciens Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 2.10 3.79 4.15 1.63

Cosciens Biopharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$11.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosciens Biopharma  (TSX:CSCI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Cosciens Biopharma Research & Development Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
Executives
Dennis Turpin Director
Gilles Gagnon Director